In June 2006, the FDA approved a vaccine for the prevention of HPV-related genomes for girls and women ages 9-26. Since then, much has been written about what has been called a prevention breakthrough. We've included some information here, for the purposes of furthering that discussion.HPV Vaccine Info
Files:
-
The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine
- Uploaded:
- 03.09.10
- File Size:
- 399 KB
- Downloads:
- 162
- Version:
- 1.0
James P. Hughes,1 Geoff P. Garnett,2 and Laura Koutsky3
-
Human Papillomavirus: Confronting the Epidemic— A Urologist’s Perspective
- Uploaded:
- 03.09.10
- File Size:
- 77 KB
- Downloads:
- 182
- Version:
- 1.0
Richard A. Watson, MD, FACS
Department of Surgery (Urology), UMDNJ New Jersey Medical School; Department of Urology,
Hackensack University Medical Center, Hackensack, NJ -
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
- Uploaded:
- 03.09.10
- File Size:
- 224 KB
- Downloads:
- 153
- Version:
- 1.0
The New England Journal of Medicine
May 10, 2007 vol. 356 no. 19
-
HPV vaccine and the future of HPV disease
- Uploaded:
- 03.09.10
- File Size:
- 26 KB
- Downloads:
- 172
- Version:
- 1.0
From: NanoVir, LLC
Results 1 - 4 of 4
News Timeline
- 03/31/2011 Radio Interview with Chris Fisher on The Doctor’s Radio Show
- 08/10/10 - Kalamazoo-based NanoVir receives $3 million NIH grant
- 05/11/10 - NanoVir scientists awarded $1.83 million NIH grant
- 06/02/08 - NanoVir, LLC Receives $3M Preclinical Development NIAID Grant
- 11/11/07 - NanoVir Scientific Director Speaks at Beijing Conference